These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 9628244

  • 1. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P, Hildebrandt G, Schaeffer HJ, Schönau E, Klug N.
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [Abstract] [Full Text] [Related]

  • 2. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, Ferone D, Barreca A.
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 4. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM.
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [Abstract] [Full Text] [Related]

  • 5. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
    Wiesli P, Zwimpfer C, Zapf J, Schmid C.
    Acta Obstet Gynecol Scand; 2006 Apr; 85(8):900-5. PubMed ID: 16862465
    [Abstract] [Full Text] [Related]

  • 6. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
    Carlsen SM, Svartberg J, Schreiner T, Aanderud S, Johannesen O, Skeie S, Lund-Johansen M, Fougner SL, Bollerslev J, POTA study group.
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
    [Abstract] [Full Text] [Related]

  • 7. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC, Rossi A, Martinelli CE, Machado HR, Moreira AC.
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [Abstract] [Full Text] [Related]

  • 8. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U, Quabbe HJ.
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [Abstract] [Full Text] [Related]

  • 9. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [Abstract] [Full Text] [Related]

  • 10. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
    Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW, van der Lely AJ, de Herder WW.
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
    [Abstract] [Full Text] [Related]

  • 11. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC, Lugao HB, Pereira MC, Machado HR, Castro Md, Moreira AC.
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [Abstract] [Full Text] [Related]

  • 12. Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
    Levitt NS, Ratanjee BD, Abrahamson MJ.
    Horm Metab Res; 1995 Apr; 27(4):185-8. PubMed ID: 7750902
    [Abstract] [Full Text] [Related]

  • 13. Homocysteine levels in acromegaly patients.
    Hekimsoy Z, Ozmen B, Ulusoy S.
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [Abstract] [Full Text] [Related]

  • 14. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

  • 15. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
    Pekic S, Doknic M, Miljic D, Joksimovic M, Glodic J, Djurovic M, Dieguez C, Casanueva F, Popovic V.
    Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
    [Abstract] [Full Text] [Related]

  • 16. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C, Fatti L, Camboni MG, Porcu L, Danesi L, Delitala G, Cavagnini F.
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [Abstract] [Full Text] [Related]

  • 17. Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery.
    Chen HS, Wu TE, Jap TS, Hsiao LC, Lin HD, Lee SH, Lin SH.
    Horm Metab Res; 2011 Jun; 43(6):433-9. PubMed ID: 21538290
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P, Di Somma C, Pratt KL, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfeld RG.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU, Post KD, Powell JS, Wardlaw SL.
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.